Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry

BMC Veterinary Research

Volumn 6, Issue , 2010, Pages

  Sassi, Francesco ^a   Benazzi, Cinzia ^a   Castellani, Gastone ^a   Sarli, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANIS FAMILIARIS;

TUMOR MARKER;

ANIMAL; ARTICLE; CLASSIFICATION; DOG; DOG DISEASE; EXPERIMENTAL NEOPLASM; FEMALE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; UDDER;

ANIMALS; DOG DISEASES; DOGS; FEMALE; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; TUMOR MARKERS, BIOLOGICAL;

EID: 77951887041     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/1746-6148-6-5     Document Type: Article

References (37)

1. Perou CM, Sorlie T, Eisen MB, Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale A-L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
3. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown O, Børresen-Dale A-L, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
4. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz Orrico A, Dreher D, Palazzo JP, Perreard L, Nelson E, Mone M, Hansen H, Mullins M, Quackenbush JF, Ellis MJ, Olopade OI, Bernard PS, Perou CM. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96. 10.1186/1471-2164-7-96, 1468408, 16643655.
5. Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Børresen-Dale A-L. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006, 7:127. 10.1186/1471-2164-7-127, 1489944, 16729877.
6. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006, 355:560-569. 10.1056/NEJMoa052933, 16899776.
7. Conforti R, Boulet T, Tomasic G, Taranchon E, Arriagada R, Spielmann M, Ducourtieux M, Soria JC, Tursz T, Delaloge S, Michiels S, Andre F. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotheraphy: a biomarker study from two randomized trials. Ann Oncol 2007, 18(9):1477-1483. 10.1093/annonc/mdm209, 17515403.
8. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14(5):1368-1376. 10.1158/1078-0432.CCR-07-1658, 18316557.
9. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006, 37:1217-1226. 10.1016/j.humpath.2006.04.015, 16938528.
10. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Da{ogonek}browska N, Bardin-Mikolajczak A, Zatonsky W, Cartun R, Mandich D, Rymkiewicz G, LIgaj M, Lukaszek S, Kordek R, García-Closas M. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007, 16(3):439-443. 10.1158/1055-9965.EPI-06-0806, 17372238.
11. Misdorp W. Quelques aspects comparatifs des cancers de la mammelle chez la chienne, la chatte et la femme. Rec Med Vet Ec Alfort 1972, 148:583-590.
12. Strandberg JD, Goodman DG. Animal model of human disease: Canine mammary neoplasia. Am J Path 1974, 75(1):225-228. 1910803, 4825616.
13. Misdorp W, Esle RW, Hellmén E, Lipscomb TP. Histological Classification of Mammary Tumors of the Dog and Cat. 1999, Published by the Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology and the World Health Organization Collaborating Centre for Worldwide Aderence on Comparative Oncology. Washington, DC.
14. Misdorp W. Tumors of the mammary gland. Tumors in Domestic Animals 2002, 575-606. Iowa State Press, Ames, IA, Meuten DJ, 4.
15. Rosen PP. Myoepithelial Neoplasms. Rosen's breast pathology 2001, 425-453. Lippincott Williams & Wilkins, Philadelphia, PA, 2.
16. Brearley MJ. Mammary gland tumours in the dog. In Pract 1989, 11(6):248-253.
17. Brodey RS, Goldschmidt MH, Roszel JR. Canine mammary gland neoplasms. J Am Anim Hosp Assoc 1983, 19:61-90.
18. Nieto A, Peña L, Pérez-Alenza MD, Sànchez MA, Flores JM, Castanõ M. Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: clinical and pathologic associations and prognostic significance. Vet Pathol 2000, 37:239-247. 10.1354/vp.37-3-239, 10810988.
19. Millanta F, Calandrella M, Bari G, Niccolini M, Vannozzi I, Poli A. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Res Vet Sci 2005, 79:225-232. 10.1016/j.rvsc.2005.02.002, 16054892.
20. De Las Mulas JM, Ordás J, Millán Y, Fernández-Soria V, Cajal SR. Oncogene HER-2 in canine mammary gland carcinomas. Breast Cancer Res Treat 2003, 80:363-367. 10.1023/A:1024929730165, 14503809.
21. Ahern TE, Bird RC, Bird AE, Wolfe LG. Expression of the oncogene c-ERBB-2 in canine mammary cancers and tumor-derived cell lines. Am J Vet Res 1996, 57(5):693-696.
22. Gama A, Alves A, Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchows Arch 2008, 453:123-132. 10.1007/s00428-008-0644-3, 18677512.
23. Lagadic M, Estrada M. Tumeurs mammaires de la chienne: critères du prognostic histologique et interèt d'un grading. Rec Med Vet Ec Alfort 1990, 166(11):1035-1042.
24. Gilbertson SR, Kurzman ID, Zachrau RE, Hurvitz AI, Black MM. Canine mammary epithelial neoplasms: biological implications of morphologic characteristics assessed in 232 dogs. Vet Pathol 1983, 20:127-142.
25. Millanta F, Calandrella M, Citi S, Della Santa D, Poli A. Overexpression of HER-2 in Feline Invasive Mammary Carcinomas: Immunohistochemical Survey and Evaluation of Its Prognostic Potential. Vet Pathol 2005, 42:30-34. 10.1354/vp.42-1-30, 15657269.
26. Contesso G, Mouriesse H, Friedman S, Genin J, Sarrazin D, Rouesse J. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987, 5:1378-1386.
27. Andrè F, Domont J, Delaloge S. What can breast cancer molecular sub-classification add to conventional diagnostic tools?. Ann Oncol 2007, 18(Suppl 9):ix33-ix36. 10.1093/annonc/mdm291, 17631593.
28. Misdorp W, Hart AAM. Prognostic factors in canine mammary cancer. J Natl Cancer Inst 1976, 56(4):779-786.
29. Parodi AL. Les éléments du prognostic des cancers mammaires de la chienne. Prat Med Chir Anim Comp 1983, 18(2):31-36.
30. Peña LL, Nieto AI, Pérez-Alenza D, Cuesta P, Castaño M. Immunohistochemical detection of Ki67 and PCNA in canine mammary tumors: relationship to clinical and pathological variables. J Vet Diagn Invest 1998, 10:237-246.
31. Sarli G, Preziosi R, Benazzi C, Castellani G, Marcato PS. Prognostic value of histological stage and proliferative activity in canine malignant mammary tumors. J Vet Diagn Invest 2002, 14(1):25-34.
32. De las Mulas JM, Millán Y, Dios R. A prospective analysis of immunohistochemically determined estrogen receptor and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet Pathol 2005, 42:200-212. 10.1354/vp.42-2-200, 15753474.
33. Brunetti B, Sarli G, Preziosi R, Monari I, Benazzi C. E-cadherin and β-catenin reduction influence invasion but not proliferation and survival in canine malignant mammary tumours. Vet Pathol 2005, 42:781-787. 10.1354/vp.42-6-781, 16301574.
34. Gama A, Paredes J, Gärtner F, Alves A, Schmitt F. Expression of E-cadherin, P-cadherin and b-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival. Vet J 2008, 177:45-53. 10.1016/j.tvjl.2007.05.024, 17631398.
35. Hellmén E. Complex mammary tumours in the female dog: a review. J Dairy Res 2005, 72:90-97. 10.1017/S002202990500124X, 16180726.
36. Laasko M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Bergh J, Isola J. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006, 12(14):4185-4191. 10.1158/1078-0432.CCR-06-0353, 16857790.
37. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.